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Targeted Survival Improvements in Clinical Trials: Are You an
Absolutist or Relativist?
James Paul, BSc
The design of a clinical trial is a complex business that requires careful consideration of several factors, with one of the
most crucial being the assessment of the targeted improvement in the primary outcome measure, which is also one of
the principal determinants of sample size. The article by Castonguay et al in the current issue of Cancer1 reviews the ac-
curacy with which the median progression-free survival (PFS) and overall survival (OS) in the control arm have been
estimated in studies of epithelial ovarian cancer over the past 10 years, and in doing so they have highlighted that the
design process is even more challenging than was perhaps believed. Their primary observation is that the median OS in
the control arm was underestimated by >25% in 80% of the trials they examined (12 of 15 trials); by way of contrast,
the median PFS or time to disease progression (TTP) was underestimated by 25% in 20% of the trials studied (4 of 20
trials). In those studies in which significant underestimation occurred, the authors noted the detrimental impact on the
power to detect absolute differences in these endpoints.1
Conventionally, the overall sample size for a clinical trial with a time-to-event endpoint depends on:
1. the targeted improvement in the hazard ratio (relative improvement in the median OS, PFS, or TTP); and
2. the type I and type II error (equivalently significance level and power)
Together, these 2 factors determine the number of events required (deaths/disease progressions). The following fac-
tors then determine the sample size required to observe the required number of events:
1. the median time to the event in the control arm (median OS, PFS, or TTP);
2. the accrual rate; and
3. the minimum follow-up period.
Modest variations in the accrual rate and median time to outcome in the control arm are to be expected and can be
accommodated (within reason) by adjustment of the recruitment period or minimum follow-up time or both to achieve
the required number of events specified in the study design. This ensures the correct type II error/study power for the rela-
tive improvement in median time to outcome.
However, it must be noted that the sample size calculation operates within the context of a targeted improvement
that is a relative one. Although it is the relative improvement that is used by the statistician in the calculation of the sample
size, the absolute difference is also an important and interlinked consideration, possibly even the primary focus from a
clinical perspective and perhaps slightly neglected by the statistician.
The statistician takes comfort in the fact that by attaining the original number of target events specified in the design,
power is maintained to detect the relative difference between the treatment arms whatever the underlying median time to
outcome. Expanding on the point made by Castonguay et al1 in Table 3 of their article, Table 1 presented herein shows
how the absolute difference that can be detected with the stated study power varies as the median survival is underesti-
mated by varying amounts; it also demonstrates how the power to detect the original target absolute difference declines. It
should be emphasized that the power to detect the relative difference (specified in the hazard ratio) is maintained in all
cases.
Corresponding author: James Paul, BSc, Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, The Beatson West of Scot-
land Cancer Centre, Level 0, 1053 Gt. Western Rd, Glasgow, G12 0YN UK; Fax: (011) 44 (0) 141 301 7189; james.paul@glasgow.ac.uk
Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
VC 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Crea-
tive Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.
See referenced original article on pages 413-22, this issue.
DOI: 10.1002/cncr.29031, Received: August 10, 2014; Accepted: August 14, 2014, Published online October 2, 2014 in Wiley Online Library (wileyonlinelibrary.
com)
Cancer February 1, 2015 335
Editorial
As can be seen in Table 1, as the control arm median
is increasingly underestimated, only larger absolute differ-
ences can be detected with the power stated in the design.
Equivalently, the more the control arm median is underes-
timated, the less the power to detect the original absolute
target improvement. The effect on the absolute difference
that can be detected is less when dealing with smaller
medians, such as would typically apply for an endpoint
such as PFS. It is interesting to note that starting with a
study design with a higher power (90% rather than 80%)
means that even at the higher level of underestimation
given in Table 1 (a 25% difference), reasonable power is
maintained to detect the original absolute target (75%).
What is a sufficient change in the absolute difference
that can be reliably detected that would require study modi-
fication? One would argue perhaps that a change from 6
months to 7.5 months might be worth considering starting
to make a modification for, but not a change from 3
months to 3.75 months? It is difficult to make a definitive
judgment without understanding more about how the dif-
ference to be detected in the study has been determined in
the first place. A study is designed around a single important
target difference, but in reality there are shades of gray
around what is an “important” difference. The DELTA pro-
ject (Difference ELicitation in TriAls) conducted within the
United Kingdom2 examined how trialists determined the
targeted difference in clinical trials. This study concluded
that there was a need for more formal methods with which
to determine the target difference and improved reporting
of its specification. In particular, reporting should “state the
underlying basis used for specifying the target difference:
 An important difference as judged by a stakeholder or
 A realistic difference based on current knowledge or
 Both an important and a realistic difference.”2
In addition, for survival outcomes, reporting should
“. . ..state the target difference as an absolute and/or rela-
tive difference. . .. . . If both an absolute and a relative dif-
ference are provided, clarify if either takes primacy in
terms of the sample size calculation.”2
Careful consideration of what is an important target
difference has been an issue of continued debate and is not
a straightforward process.3 It is also a process at which his-
torically the oncology community has been poor.4
Explicit consideration of this in published study reports
would help investigators and ultimately consumers of
their research understand the extent to which changes in
underlying assumptions about median outcomes in the
control arm have impacted the study objectives.
Why is so much emphasis placed on relative
improvement in outcome, when to many the absolute dif-
ference is a more natural way of thinking? This emphasis
has really come from statisticians.
The fact that statisticians approach survival in terms
of relative improvement and the associated hazard ratio is
largely a consequence of the ubiquitous use of the Cox
proportional hazards model as the primary means for ana-
lyzing survival data. This statistical approach was devel-
oped to cope with the analytical difficulties of dealing
with censored data (ie, the fact that we only observe the
time to study outcome for a percentage of the patients
TABLE 1. Impact of Variation in Observed Versus Estimated Control Arm Median on 1) Absolute Difference






























15 0.833 3 80 15 (1) 3.0 80
15 0.833 3 80 16.875 (1.125) 3.375 71
15 0.833 3 80 18.75 (1.25) 3.75 63
15 0.833 3 90 15 (1) 3.0 90
15 0.833 3 90 16.875 (1.125) 3.375 83
15 0.833 3 90 18.75 (1.25) 3.75 75
30 0.833 6 80 30 (1) 6.0 80
30 0.833 6 80 33.75 (1.125) 6.75 71
30 0.833 6 80 37.5 (1.25) 7.5 63
30 0.833 6 90 30 (1) 6.0 90
30 0.833 6 90 33.75 (1.125) 6.75 83
30 0.833 6 90 37.5 (1.25) 7.5 75
Abbreviation: HR, hazard ratio.
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taking part in the trial; for the remainder we only observe
the follow-up time without outcome).
The Cox model provides an elegant solution to this
difficulty, but as a model it is framed in terms of relative
event rates, as are the associated power and sample size cal-
culations; hence the emphasis on relative improvements
by statisticians.
It should also be noted that the Cox model is based
on the assumption of a constant relative event rate (rela-
tive hazard) over the follow-up period: the “proportional
hazards” assumption. When this assumption is not ful-
filled, the estimate of relative improvement derived from
the Cox model is not a meaningful measure of the differ-
ence in outcome between the study arms.
In recent high-profile trials,5-7 this requirement of a
constant relative rate has not been fulfilled. This has led
some to propose alternative measures,8 including an abso-
lute change in survival as measured by restricted mean sur-
vival times (RMSTs).9 The use of this measure requires a
prespecification of a follow-up time, but requires no
assumption such as a constant relative hazard (propor-
tional hazards) to be valid. The RMST itself can be inter-
preted as the life expectancy between randomization onto
the trial and a prespecified follow-up time. Some early
work has been done on trial design and analysis based
around the comparison of RMST. However, it should be
noted that the statistical design still rests heavily on the ac-
curacy of initial assumptions about time to event outcome
and much of the design methodology is yet to be fully
developed and applied in practice.
In any study, it is the role of the data monitoring
committee to monitor how closely the assumptions used
in the study design are being met as the data emerge. It is
usually within their remit to make appropriate adjust-
ments to ensure that the original objectives are fulfilled
and methods exist to allow this without affecting the type
I error.10 These methods are focused on adjustments
made to allow for inaccurate assumptions about the
recruitment rate or event rate within the context of relative
hazards and the Cox model; they do not extend to non-
proportional hazards or studies in which the focus is on an
absolute difference in the survival outcome. To my
knowledge, there are no formal methods that allow for an
adjustment to be made to the sample size in which the
focus is on an absolute difference in survival, and this is a
difficulty.
The problems with underestimation that Caston-
guay et al1 observed in studies with OS as the primary
endpoint did not appear to the same extent in studies
using PFS or TTP as a primary endpoint. The authors
speculate as to the reasons for this in their article and, as
they suggest, the introduction of more effective treatments
and clinical management into second-line and subsequent
treatment must be considered to play a role.1
This again raises the issue concerning the most
appropriate primary endpoint for phase 3 studies. The use
of OS is likely to become increasingly less relevant as the
influence of subsequent treatments dilutes the effect of
the intervention of primary interest and thus impacts on
the sensitivity of the trial to detect differences. To these
arguments we can now add evidence of the difficulty of
reliably planning studies around a primary endpoint
of OS.
Saad and Buyse11 recently argued that “. . ...PFS or
other tumor-based end points be considered in public
health decisions when multiple lines of effective therapies
are available in clinical practice, as long as the intervention
of interest displays a favorable toxicity profile and no
untoward effect on OS.” Adoption of PFS as a primary
endpoint is becoming an increasingly attractive option in
several settings, although strong arguments to the contrary
have been made.12
In the context of randomized phase 2 studies in
which PFS is ubiquitous, some comfort can be taken from
the fact that the shorter median PFS times indicate that the
impact of underestimation is less on absolute targets; this is
particularly important within the context of biomarker-
enriched studies in which there may be no reliable historical
information regarding the background PFS distribution on
which to base the study design.
The article by Castonguay et al1 highlights an impor-
tant practical issue in the study design of recent phase 3 stud-
ies among patients with epithelial ovarian cancer. In addition,
their findings have broader implications in that they:
 Suggest that more careful reflection is required on the
primary focus (relative or absolute improvement in the
time to even a primary endpoint) and how clinically rel-
evant differences are determined.
 Highlight further issues with the selection of OS as a
primary endpoint.
 Provide further motivation for questioning the preva-
lent standard statistical approach used to design and an-
alyze studies with time to event outcomes.
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